Skip to main content

Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies

The Original Article was published on 20 May 2021

Correction to: Translational Neurodegeneration (2021) 10:16 https://doi.org/10.1186/s40035-021-00240-7

Following publication of the original article [1], the authors would like to correct a formula from “T > C” to “C > T” in two paragraphs.

  1. 1.

    In the third paragraph of the section Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), the correct sentence should be:

However, the synonymous C > T substitution in SMN2 exon 7 alters an exonic splicing enhancer into an exonic splicing silencer, which predominantly leads to an unstable transcript missing exon 7.

  1. 2.

    In the fourth paragraph of the section Splice-switching AOs, the correct sentence should be:

The C > T substitution in SMN2 creates an exon-splicing silencer and leads to the omission of exon 7 and an unstable SMN protein that is subject to rapid ubiquitinproteasome degradation.

In addition, the authors identified an error in Fig. 4. The correct figure is given below:

Fig. 4
figure 4

Milestones of the development of antisense oligonucleotide therapeutics (excluding siRNA) from bench to bedside. Approved drugs in red are splice-switching antisense oligomers. AO: antisense oligonucleotides; FDA: US Food and Drug Administration; CMV: cytomegalovirus retinitis (in immunocompromised patients); HoFH: Homozygous familial hypercholesterolemia; DMD: Duchenne muscular dystrophy; SMA: spinal muscular atrophy; HTA: Hereditary transthyretin-mediated amyloidosis; BD: Batten disease

The original article [1] has been corrected.

Reference

  1. 1.

    Li, et al. Transl Neurodegener. 2021;10:16.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to May Thandar Aung-Htut.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, D., McIntosh, C.S., Mastaglia, F.L. et al. Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. Transl Neurodegener 10, 41 (2021). https://doi.org/10.1186/s40035-021-00267-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40035-021-00267-w